

Figure 1C

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7





Figure 8

MOI=500



(B-6-detached Iysate)
Control
AdLACZAp1
AdLACZAp2
AdSusb360LacZ

Figure 9





Figure 10



W C E D D P W H G Z E E A C S S D

Std. d17001 AdLacZΔpol




Figure 11

Figure 12





Figure 13






Figure 14




Figure 15




Figure 16

Adsub360LacZ AdLacZΔpol AdLacZΔpp






Figure 17

Figure 18



pAdAsCL- Δ IVa2 shuttle plasmid(\sim 14.2kb) Amp-Res


Linearization sites




← primer site location of indicated primer

Figure 19

Figure 20





E1+pol+pTP+IVa2+100K= Lanes 1-4

E1+100K=Lane 5

E1= Lane 6

Figure 21

Figure 22




FIG. 23




Figure 24




Figure 25




Figure 26



Figure 27




Figure 28




Figure 29




Figure 30





Figure 31







Figure 32

Figure 33







Figure 34

Figure 35


© 2006 Blackwell Publishing Ltd, *Journal of Internal Medicine*, 260, 43–52

Untreated AdhGAA-treated



pAdAsclL-ΔIVa2,Δpp- 1.6kb:intermediate shuttle plasmid(\sim 12.6kb) Amp-Res

Linearization sites




←primer site location of indicated primer

Figure 36

pAdAscl-ΔIVa2,Δpp-2.4kb shuttle plasmid(\sim 11.8kb)

Amp-Res

Linearization sites




← primer site location of indicated primer

Figure 37

pAdAscl-ΔIVa2,Δpol shuttle plasmid(\sim 13.6kb)

Amp-Res

Linearization sites



← primer site location of indicated primer

Figure 38